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Prevention of the progression of chronic kidney disease: Prac-
tice in China. With the epidemic rise of end-stage renal disease
(ESRD) in many countries of the world, there is an urgent need
to develop and implement strategies aiming at preventing the
development and progression of chronic kidney disease (CKD),
and the situation is the same in China. Glomerulonephritis is
still the most common cause of ESRD in China; however, epi-
demiologic studies have revealed that the prevalence of dia-
betes and hypertension, which both are major causes of ESRD
in many developed countries, are increasing dramatically. Ad-
ditional studies about the prevalence of albuminuria in diabetes
mellitus (DM) patients, and the prevalence of kidney lesion in
certain high-risk population (e.g., hypertension and atheroscle-
rosis) are undergoing. According to a questionnaire survey and
some reports, education program for Chinese nephrologists and
practitioners should to be strengthened.
Chronic kidney disease (CKD) is a major public health
problem that is associated with escalating health care
costs. There are about 1 million people in the world de-
pendent on renal replacement therapy (RRT) to keep
them alive [1]. CKD patients on RRT are associated
with profound mortality and mortality. China is a vast
developing country with broad territory and a huge pop-
ulation of 1.3 billion. According to the Chinese Dialysis
and Transplantation Registration Report, 41,755 patients
underwent maintenance dialysis in 1999 [2]. The preva-
lence and the annual incidence rate of dialysis were
33.2 per million population (pmp) and 15.3 pmp, re-
spectively [2]. Newer data from Shanghai (a metropolis
of China) reported by Shanghai Hemodialysis Quality
Control Center and Shanghai Dialysis and Transplanta-
tion Registration Group indicated that 6521 patients had
received maintenance dialysis by the end of 2002, and
31.9% of them initiated dialysis within 2002. The annual
incidence rate of dialysis was 148.1 pmp, which was def-
initely higher than that in 1999. Beijing Dialysis Qual-
ity Control Center reported the annual incidence rate of
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hemodialysis was 146.4 pmp in 2002 and 279.6 pmp in
2003, and there were 4163 patients on RRT until Decem-
ber 2003. Obviously, the burden of CKD has emerged
as a prominent problem in China, and there is an urgent
need to develop and implement strategies aiming at pre-
venting the development and progression of CKD, which
should include population-based high risk screening pro-
grams for early detection, dissemination, and education
of evidence-based guidelines for slowing disease pro-
gression. Currently, some prospective and cross-sectional
studies targeted at improving practice of prevention the
progression of CKD have been implemented or are in
progression.
COMMUNITY-BASED SCREENING AND
HIGH-RISK POPULATION DETECTION
Unlike North America and many developed coun-
tries, where the major causes of end-stage renal disease
(ESRD) are diabetes mellitus (DM) and hypertension,
the leading cause of ESRD in China was glomeru-
lonephritis (49.9%), followed by diabetic nephropathy
(DN, 13.3%) and hypertensive nephrosclerosis (9.6%), as
reported by Chinese Dialysis and Transplantation Regis-
tration Group in 1999 [2] (Fig. 1). The constituent had no
significant changes in the past three years, according to
Shanghai Dialysis and Transplantation Registration Re-
port in 2003 (Fig. 2).
Several epidemiologic studies have been performed to
understand if there is an increasing tendency of metabolic
disorders and their related renal diseases. A nationwide
screening of DM in 1996, which included 42,751 peo-
ple aged 20 to 75 years old from 11 provinces, indicated
that the prevalence of DM and impaired glucose toler-
ance (IGT) was 3.21% and 4.76%, respectively [3]. By
contrast, in 1979, the prevalence of DM was only 1.0%
[4]. With the fold increase in diabetes prevalence, DM
has become a major problem for public health in China,
and it is projected that there will be 38 million DM pa-
tients in 2025. Recently, China conducted two large stud-
ies of prevalence of microalbuminuria in DM patients.
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Fig. 1. Etiology of end-stage renal disease re-
ported by Chinese Dialysis and Transplanta-
tion Registration Group in 1999.
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Fig. 2. Etiology of end-stage renal disease re-
ported by Shanghai Dialysis and Transplanta-
tion Registration Group in 2002.
In Microalbuminuria Prevalence Study (MAPS), the
prevalence of macro- and microalbuminuria was 17.0%
and 42.9% respectively, among 2466 type 2 DM patients
with hypertension (Pan CY, personal communication). In
another program—DEMAND (Developing Education
on Microalbuminuria for Awareness of Renal and car-
diovascular risk in Diabetics), analysis of 5143 Chinese
diabetes patients revealed that the prevalence of macro-
and microalbuminuria was 3.1% and 41.0%, respectively
(Pan CY, personal communication).
The prevalence of hypertension also has increased sig-
nificantly in China. According to the epidemiologic study
from 1958 to 1959, the prevalence of hypertension was
5.11% [5]. It increased to 7.73% in another epidemio-
logic study from 1979 to 1980 that involved 4,012,128
people from 29 provinces [6]. In the 1990s, the preva-
lence of hypertension climbed to 11.26%, which was an
increase of 25% in about 10 years, and it was estimated
that there were more than 90 million hypertensive pa-
tients in China in 1991 [7]. At the same time, the rate
of awareness, treatment, and control was only 26.3%,
12.1%, and 2.8%, respectively [7], which is far lower than
data released by NHANES III in United States [8]. Since
the elevated serum creatinine and albuminuria are closely
related to the level of blood pressure [9, 10], an epidemi-
ologic study is ongoing at a community of the urban area
of Beijing to estimate the prevalence of renal impairment
in hypertension patients. Around 6000 residents older
than 40 years old will be screened, and those with hy-
pertension will be tested for microalbuminuria (urinary
albumin/creatinine ratio) and estimated glomerular fil-
tration rate (GFR) (MDRD equation). Even renal artery
stenosis is not the major cause of ESRD; the annual-
ized percentage of the growth of RVD-ESRD was two
times higher than all causes of ESRD, and even higher
than DN [11]. In the 1980s, the most common cause of
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renovascular hypertension in China was Takayasu arteri-
tis (68.6%) [12]. However, since 1990, atherosclerotic
renal artery stenosis (ARAS) has become the leading
etiology of renal artery stenosis (71.1%) (unpublished
data). Several cross-sectional or prospective studies re-
vealed that the prevalence of ARAS in atherosclerotic
vascular disease population (e.g., coronary artery disease,
peripheral arterial disease, and stroke) is comparable to
reports from developed countries. For example, 19.1%
to 34.5% of patients with coronary artery disease (sam-
ple size varied from 128 to 467) were combined with
renal artery stenosis [13–15, unpublished data]. And in
patients with peripheral arterial disease and stroke, the
prevalence of ARAS was 30.0% and 40.0%, respectively
(unpublished data). One important feature of ARAS is is-
chemic nephropathy. The analysis of ischemic nephropa-
thy secondary to ARAS in China indicated that at first
consultation, only 37.5% had normal serum creatinine
(<13 lmol/L) and nonatrophied kidneys (unpublished
data), which suggested the keen necessity of screening
ARAS in high-risk population. A cross-sectional study
of the prevalence of ARAS in urban residents with mul-
tiple atherosclerotic high-risk factors (such as smoking,
dyslipidemia, and DM) is being carried out in Beijing with
the intention to understand high-risk factors of ischemic
nephropathy.
Glomerulonephritis is still the most common cause of
ESRD in China, but the at-risk population for glomeru-
lonephritis is still unclear. A population-based epidemi-
ologic study about the prevalence of renal diseases and
the risk factors of glomerulonephritis is now going on in
Beijing. The recruited population has been adjusted by
regions, age, and sex distribution. Besides general screen-
ing targets, infectious factor (especially upper respira-
tory infection and HBV infection) and history of using
nephrotoxic medications are included.
APPLICATION OF THE CURRENT CONSENSUS
ON PREVENTION OF THE PROGRESSION
OF CKD
An epidemiologic survey in Shanghai revealed that
cardiovascular complications occurred in 86% of 1093
ESRD patients [16]. A nationwide registration also
demonstrated that almost 50% death of chronic dialysis
was caused by cardiovascular complications [2]. So it is
the consensus that prevention of the progression of CKD
and the cardiovascular complications are two targets of
the treatment of CKD.
In April 2004, an International Symposium on Inte-
grated Therapy of CKD was convened in Beijing under
the sponsorship of COMGAM-ISN and KDI/GO. At the
beginning of the Symposium, 143 participating nephrol-
ogists from 20 provinces received a questionnaire sur-
vey about prevalent practice habits in CKD management.
When asked about guidelines use, 67.1% of nephrologists
use K/DOQI clinical practice guidelines, and 38.5% use
the Chinese textbook as the source of references. Anal-
ysis of the questionnaire showed that most of the partic-
ipating nephrologists did pay attention to the important
timely comorbidities (Fig. 3), and deemed blood pressure
control and restriction of protein intake as the most im-
portant procedures in prevention of CKD progression in
nondiabetics and diabetic patients, as well as blood glu-
cose control in the latter (Fig. 4). Since not every patient
with renal failure has the opportunity to receive dialy-
sis, the use of angiotensin-converting enzyme inhibitor
(ACEI)/angiotensin receptor blocker (ARB) was usually
withdrawn after serum creatinine over 4 mg/dL (Fig. 4).
To investigate the status of clinical control of renal
parenchymal hypertension in China, 1684 patients were
enrolled in a cross-sectional study from 15 provinces
from 1999 to 2000 [17]. Compared with relatively poor
treatment status of primary hypertension, the awareness
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Fig. 4. Procedures of prevention of CKD
progression in nondiabetic and diabetic pa-
tients.
and treatment rate was 76.4% and 78.2%, respectively
[17], and control rate was 25.5% and 11.8% if using
<140/90 mm Hg or <130/80 mm Hg as criteria [17]. Pa-
tients who were treated in larger centers and were hos-
pitalized tended to have higher rates of awareness rate,
while culture background and sex had no effect on aware-
ness and treatment [17]. Major causes of noncompli-
ance included deeming unnecessary (54.0%), uncertainty
about the necessity of long-term treatment (27.0%), and
forgetting to take medications (15.5%) [17]. It indicated
that the unsatisfied therapy could be improved through
education. Besides definite influences of renal function
and histologic lesions, patients treated in the hospital with
formal nephrology centers had higher control rates than
those in the general hospital [17], which suggests early
referral to nephrologists is recommended. Among those
treated patients, 40.4% of nondiabetic patients and 32.8%
of diabetic patients received ACEI from 1999 to 2000 [17].
Recently, a meta-analysis concluded that lipid reduction
may preserve GFR and may decrease proteinuria in pa-
tients with renal disease [18]. To evaluate the status of
lipids control, a multicenter study enrolling 2136 patients
from different departments in 25 centers indicated that
control rate of hypercholesterolemia in renal division was
20.2%, which is comparatively lower than that in the car-
diovascular division, endocrine division, and neurology
division (27.7%, 24.4%, and 25.2%, respectively) [19].
CONCLUSION
The first Chinese medical textbook in 2600 BC,
Huangdee Medicine, indicated that the inferior doctors
treat full-blown disease, while the superior doctors pre-
vent disease [20]. Currently in China, the identification
of high-risk populations and early diagnosis of CKD
through population-based epidemiologic studies or high-
risk population epidemiologic studies and the integrated
treatment of CKD are going on. The education program
for Chinese nephrologists and practitioners should be
strengthened and disseminated.
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